Key result
Carvedilol significantly ameliorated dexamethasone-induced myocardial injury in rats, an effect that was potentiated by the α1-agonist phenylephrine and exceeded by the non-selective β-blocker propranolol.
Why the study?
The study aimed to investigate the cardiotoxic effects of high-dose dexamethasone in rats, the therapeutic effect of carvedilol, and the role of the alpha 1-adrenergic receptor.
Does carvedilol ameliorate dexamethasone-induced myocardial injury in rats, and is this effect independent of its action on the α1-adrenergic receptor?
Does carvedilol ameliorate dexamethasone-induced myocardial injury in rats, and is this effect independent of its action on the α1-adrenergic receptor?
p-value: p=<0.05
Carvedilol protects against dexamethasone-induced cardiotoxicity in rats, but its inherent α1-adrenergic blocking activity paradoxically attenuates this cardioprotective effect compared to non-selective β-blockers.
Carvedilol's α1-blockade may attenuate protection against dexamethasone cardiotoxicity in rats; leaves open whether β1-selective agents are superior in this model.
The current study aimed to investigate the cardiotoxic effect of dexamethasone-high-dose in rats, the therapeutic effect of carvedilol and the role of α1-adrenergic receptor (α1AR). The experiment involved 6 groups: control, dexamethasone (10 mg/kg), carvedilol (10 mg/kg), phenylephrine (1 mg/kg), phenylephrine plus carvedilol and propranolol (30 mg/kg). Drugs and vehicles were given for 7 days. Dexamethasone was given with the drugs in the last 4 groups. On the 8 th -day and after overnight fasting, serum and cardiac samples were collected. Serum levels of cardiac troponin I and creatine kinase–myoglobin as well as cardiac levels of diacylglycerol, malondialdehyde, kinase activity of Akt, transforming growth factor-β, Smad3 and alpha smooth muscle actin were measured. Cardiac samples were also used for histopathological examination using hematoxylin–eosin and Sirius red stains, in addition to immunohistochemical examination using β-arrestin2 antibody. Dexamethasone induced cardiac injury via increasing oxidative stress, apoptosis and profibrotic signals. Carvedilol significantly reduced the dexamethasone-induced cardiotoxicity. Using phenylephrine, a competitive α1-agonist, with carvedilol potentiated the cardioprotective actions of carvedilol. Propranolol, a β-blocker without activity on α1ARs, showed higher cardiac protection than carvedilol. Dexamethasone-high-dose upregulates cardiac oxidative stress, apoptotic and profibrotic signals and induces cardiac injury. Blocking the α1-adrenergic receptor by carvedilol attenuates its cardioprotective effects against dexamethasone-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Mohamed et al. (2022) studied Dexamethasone-induced myocardial injury (n=54). Carvedilol vs. Dexamethasone alone was evaluated on Myocardial injury (serum cTnI and CK-MB levels) (p=<0.05). Carvedilol significantly ameliorated dexamethasone-induced myocardial injury in rats, an effect that was potentiated by the α1-agonist phenylephrine and exceeded by the non-selective β-blocker propranolol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: